In a filing, Acrivon Therapeutics Inc revealed its 10% Owner PERCEPTIVE ADVISORS LLC unloaded Company’s shares for reported $0.62 million on Apr 30 ’25. In the deal valued at $1.41 per share,437,881 shares were sold. As a result of this transaction, PERCEPTIVE ADVISORS LLC now holds 3,403,025 shares worth roughly $3.57 million.
Then, PERCEPTIVE ADVISORS LLC sold 298,886 shares, generating $400,507 in total proceeds. Upon selling the shares at $1.34, the 10% Owner now owns 3,104,139 shares.
Before that, PERCEPTIVE ADVISORS LLC sold 1,054,669 shares. Acrivon Therapeutics Inc shares valued at $2,056,605 were divested by the 10% Owner at a price of $1.95 per share. As a result of the transaction, PERCEPTIVE ADVISORS LLC now holds 4,306,189 shares, worth roughly $4.52 million.
A number of analysts have revised their coverage, including KeyBanc Capital Markets’s analysts, who began to cover the stock in late January with a ‘”an Overweight”‘ rating. Ladenburg Thalmann also remained covering ACRV and has increased its forecast on September 16, 2024 with a “Buy” recommendation from previously “Neutral” rating. Ladenburg Thalmann revised its rating on April 29, 2024. It rated ACRV as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ACRV
On Friday, Acrivon Therapeutics Inc [NASDAQ:ACRV] saw its stock fall -4.55% to $1.05. Over the last five days, the stock has lost -8.70%. Acrivon Therapeutics Inc shares have fallen nearly -82.56% since the year began. Nevertheless, the stocks have fallen -86.40% over the past one year. While a 52-week high of $10.16 was reached on 02/05/25, a 52-week low of $1.06 was recorded on 05/30/25. SMA at 50 days reached $1.8256, while 200 days put it at $5.6398.
Levels Of Support And Resistance For ACRV Stock
The 24-hour chart illustrates a support level at 1.0200, which if violated will result in even more drops to 0.9900. On the upside, there is a resistance level at 1.1100. A further resistance level may holdings at 1.1700. The Relative Strength Index (RSI) on the 14-day chart is 31.04, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0574, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 100.00%. Stochastics %K at 12.08% indicates the stock is a buying.
The most recent change occurred on March 01, 2024 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $14 price target.
